Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
Wang T, Liu L, Fang J, Jin H, Natarajan S, Sheppard H, Lu M, Turner G, Confer T, Johnson M, Steinberg J, Ha L, Yadak N, Jain R, Picketts D, Ma X, Murphy A, Davidoff A, Glazer E, Easton J, Chen X, Wang R, Yang J. Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma. Cancer Research 2024, 85: 424-441. PMID: 39531507, PMCID: PMC11786959, DOI: 10.1158/0008-5472.can-24-1142.Peer-Reviewed Original ResearchPancreatic neuroendocrine tumorsC-mycCre recombinaseAnti-GD2 immunotherapyHigh-risk neuroblastomaDopamine B-hydroxylaseActivity of c-MycFDA-approved inhibitorC-Myc overexpressionC-Myc activityC-myc inductionTesting immunotherapyNeuroendocrine tumorsTargeted therapyTumor typesNeuroblastoma developmentNeuroblastoma tumorsNeuroblastoma oncogenesisEffective therapyTyrosine hydroxylaseTarget cellsTumorNeuroblastomaHuman neuroblastomaGenetic features
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply